Nasus Pharma (NSRX) Company presentation summary

Strategic positioning and technology

• Proprietary Nasax powder technology enhances intranasal drug absorption, targeting rapid and precise delivery for emergency medical conditions.

• Focus on well-known APIs enables a lower-risk 505(b)(2) regulatory pathway.

• Lead candidate NS002 offers a needle-free, easy-to-administer alternative to injectable epinephrine, addressing limitations of current autoinjectors.

• Robust global IP portfolio with patents granted in major markets, extending protection to at least 2038.

• Strong financial position supports ongoing clinical development and pipeline expansion.

Clinical pipeline and development milestones

• NS002 (intranasal epinephrine) has completed Phase 2 studies, showing faster and higher absorption than EpiPen® in both single and repeat dosing.

• Pivotal Phase 3 trial for NS002 is planned for Q4 2026, with NDA submission targeted for 2027.

• Additional pipeline assets include NS003 (ondansetron, preclinical), NS004 (metabolic, preclinical), NS005 (cardiovascular, preclinical), and NS001 (naloxone, pivotal Phase 3 completed).

• NS001 (intranasal naloxone) demonstrated faster and higher absorption than Narcan® in a pivotal study, validating the Nasax platform.

Market opportunity and competitive landscape

• Anaphylaxis affects 1–3% of the global population, with a $2.3B epinephrine market in 2024 and strong growth trends.

• Up to 50% of at-risk patients do not carry or refill epinephrine, highlighting unmet needs.

• NS002’s needle-free, portable format and rapid onset address key barriers to current epinephrine use.

• Competitive PK data show NS002 achieves therapeutic plasma levels faster than EpiPen® and other needle-free candidates.

• Speed of onset is highly valued by prescribers, influencing product choice.